ReviewCureus2026
Targeted Metabolic Therapy in Cancer: A Comprehensive Metabolic Treatment Strategy.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer progression arises from the convergence of three domains: intrinsic metabolic and signaling rewiring within tumor cells, microenvironmental conditions that support survival and dissemination, and systemic metabolic dysfunction in the host. These layers collectively drive treatment resistance, immune evasion, and recurrence. Targeted metabolic therapy (TMT) is proposed as a comprehensive therapeutic framework designed to simultaneously target all three domains of cancer progression. TMT targets key metabolic pathways implicated in tumor growth and survival such as glycolysis, glutaminolysis, IGF-1/PI3K-AKT-mTOR, angiogenesis, apoptosis resistance, and Wnt/β-catenin signaling, while also disrupting microenvironmental drivers including cancer stemness, metastasis, acidosis, hypoxia, and chronic inflammation. At the systemic (host) level, TMT corrects metabolic derangements - including hyperglycemia, systemic inflammation, and cachexia - that create a permissive environment for tumor progression. The therapeutic model integrates multiple intervention categories. These include dietary and fasting strategies, repurposed pharmacological agents, nutraceuticals, and essential vitamins and minerals. Additional components encompass oxygen- and redox-modulating therapies and lifestyle optimization measures. This paper outlines the biological rationale for TMT and proposes a systems-level framework for applying coordinated metabolic pressure with the aim of improving treatment responsiveness, prolonging survival, and offering cancer patients a more durable path toward disease control and remission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.